Biogen Inc. has reached an agreement with Genentech, Inc., a member of the Roche Group, related to the commercialization for glofitamab. Under the agreement, Biogen will have no payment obligations and will receive tiered royalties on potential sales of glofitamab in the U.S. as part of the companies collaboration on antibodies targeting CD20.   Glofitamab is an investigational CD20xCD3 T-cell engaging bispecific antibody being developed by Roche for the treatment of B-cell non-Hodgkin’s lymph...